Market Performance Overview
Acrivon Therapeutics (ticker: ACRV) closed the trading session on Thursday, 22 April 2026 at USD 1.83, representing a 1.67 % increase from the previous close. The share price is currently supported by a simple moving average of the last 200 trading days at USD 1.78. In the 52‑week range, the stock reached a high of USD 3.56 on 1 July 2026 and a low of USD 1.27 on 30 March 2026.
At the close, the exchange‑listed volume was 42.7 million shares outstanding. The market capitalisation stood at USD 76.9 million. In the last 24 hours, a total of USD 290.4 thousand of shares were traded. Over the most recent month, the share price declined by 15.12 %.
Comparative Performance of Related Stocks
| Company | Recent 24‑hour Movement | Current Price (USD) | Market Capitalisation (USD) |
|---|---|---|---|
| Tenaya Therapeutics (TNYA) | -4.88 % | 0.40 | 91.9 million |
| Star (STHO) | -0.53 % | 7.50 | 90.7 million |
| Bradbury Capital (BBCI) | -2.24 % | 2.14 | 90.2 million |
| Rani Therapeutics (RANI) | -7.35 % | 0.60 | 91.0 million |
| Fifth District (FDSB) | +1.11 % | 17.29 | 90.5 million |
Company Profile
Acrivon Therapeutics, Inc. is a clinical‑stage oncology company headquartered in Watertown, United States. The company focuses on oncology through a precision proteomics technology platform that supports the development of drug‑tailored companion diagnostics. This platform is designed to link drug mechanisms to active disease‑driving processes in cancer patients, thereby identifying drug sensitivity beyond the capabilities of traditional genomic analyses.
The company’s initial public offering was conducted on 10 November 2022. Acrivon Therapeutics is listed on the Nasdaq stock exchange. Further information can be found on the company’s website: https://www.acrivon.com .
